Your browser doesn't support javascript.
loading
Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10.
Huang, Mu-Yang; Chen, Yu-Chi; Lyu, Wen-Yu; He, Xin-Yu; Ye, Zi-Han; Huang, Can-Yu; He, Xin-Ling; Chen, Xiuping; Chen, Xiaobing; Zhang, Baoxian; Kai, Guoyin; Zhang, Xiaolei; Li, Ting; Huang, Mingqing; Lu, Jin-Jian.
  • Huang MY; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • Chen YC; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • Lyu WY; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • He XY; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • Ye ZH; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • Huang CY; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • He XL; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • Chen X; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China; Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region of China
  • Chen X; Increasepharm (Hengqin) Innovative Medicine Institute Limited, Zhuhai, China.
  • Zhang B; Increasepharm (Hengqin) Innovative Medicine Institute Limited, Zhuhai, China.
  • Kai G; Zhejiang Provincial International S&T Cooperation Base for Active Ingredients of Medicinal and Edible Plants and Health, School of Pharmaceutical Sciences, The Third Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
  • Zhang X; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
  • Li T; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China. Electronic address: tingli@um.edu.mo.
  • Huang M; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China. Electronic address: hmq1115@126.com.
  • Lu JJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China; Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region of China
Pharmacol Res ; 198: 106988, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37984507
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Antígeno B7-H1 Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Antígeno B7-H1 Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article